Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 14 studies | 23% ± 9% | |
adipocyte | 7 studies | 25% ± 9% | |
macrophage | 5 studies | 19% ± 3% | |
epithelial cell | 4 studies | 20% ± 5% | |
fibroblast | 4 studies | 17% ± 1% | |
astrocyte | 4 studies | 33% ± 9% | |
glutamatergic neuron | 4 studies | 44% ± 17% | |
endothelial cell of lymphatic vessel | 4 studies | 18% ± 1% | |
type I pneumocyte | 4 studies | 19% ± 3% | |
type II pneumocyte | 4 studies | 21% ± 4% | |
oligodendrocyte | 4 studies | 23% ± 6% | |
microglial cell | 3 studies | 20% ± 3% | |
hepatocyte | 3 studies | 36% ± 13% | |
GABAergic neuron | 3 studies | 49% ± 7% | |
oligodendrocyte precursor cell | 3 studies | 27% ± 6% | |
monocyte | 3 studies | 17% ± 1% | |
neuron | 3 studies | 24% ± 6% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 1307.93 | 1445 / 1445 | 100% | 15.93 | 183 / 183 |
ovary | 100% | 1436.92 | 180 / 180 | 100% | 12.42 | 430 / 430 |
lung | 100% | 1283.23 | 577 / 578 | 100% | 17.74 | 1153 / 1155 |
intestine | 100% | 1457.24 | 966 / 966 | 99% | 11.73 | 524 / 527 |
brain | 100% | 817.09 | 2634 / 2642 | 100% | 23.22 | 703 / 705 |
breast | 100% | 1596.28 | 459 / 459 | 99% | 18.20 | 1108 / 1118 |
stomach | 100% | 866.18 | 359 / 359 | 99% | 13.64 | 283 / 286 |
uterus | 100% | 1707.56 | 170 / 170 | 98% | 17.02 | 451 / 459 |
thymus | 100% | 1378.57 | 653 / 653 | 98% | 15.31 | 592 / 605 |
prostate | 100% | 1608.23 | 245 / 245 | 97% | 18.08 | 489 / 502 |
pancreas | 99% | 525.52 | 325 / 328 | 98% | 14.69 | 175 / 178 |
bladder | 100% | 1425.71 | 21 / 21 | 97% | 12.19 | 490 / 504 |
skin | 100% | 1496.87 | 1809 / 1809 | 97% | 20.66 | 456 / 472 |
kidney | 100% | 838.38 | 89 / 89 | 96% | 15.03 | 863 / 901 |
adrenal gland | 100% | 1310.60 | 258 / 258 | 93% | 13.65 | 215 / 230 |
liver | 100% | 819.04 | 226 / 226 | 91% | 10.07 | 370 / 406 |
adipose | 100% | 1786.24 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 1759.81 | 1335 / 1335 | 0% | 0 | 0 / 0 |
spleen | 100% | 1128.01 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.45 | 1 / 1 |
muscle | 100% | 1029.64 | 802 / 803 | 0% | 0 | 0 / 0 |
heart | 99% | 903.39 | 854 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 13.74 | 43 / 45 |
lymph node | 0% | 0 | 0 / 0 | 83% | 9.24 | 24 / 29 |
eye | 0% | 0 | 0 / 0 | 74% | 5.15 | 59 / 80 |
peripheral blood | 59% | 421.20 | 550 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0016567 | Biological process | protein ubiquitination |
GO_1990390 | Biological process | protein K33-linked ubiquitination |
GO_0035455 | Biological process | response to interferon-alpha |
GO_0007010 | Biological process | cytoskeleton organization |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0015031 | Biological process | protein transport |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0006895 | Biological process | Golgi to endosome transport |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0031463 | Cellular component | Cul3-RING ubiquitin ligase complex |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0030425 | Cellular component | dendrite |
GO_0005802 | Cellular component | trans-Golgi network |
GO_0015629 | Cellular component | actin cytoskeleton |
GO_0005829 | Cellular component | cytosol |
GO_0016605 | Cellular component | PML body |
GO_0005737 | Cellular component | cytoplasm |
GO_0030424 | Cellular component | axon |
GO_0019964 | Molecular function | type II interferon binding |
GO_0004842 | Molecular function | ubiquitin-protein transferase activity |
GO_0005515 | Molecular function | protein binding |
GO_0003779 | Molecular function | actin binding |
Gene name | KLHL20 |
Protein name | KLHL20 protein (Kelch-like 20 (Drosophila), isoform CRA_a) Kelch-like protein 20 (Kelch-like ECT2-interacting protein) (Kelch-like protein X) |
Synonyms | hCG_23698 KLEIP KLHLX |
Description | FUNCTION: Substrate-specific adapter of a BCR (BTB-CUL3-RBX1) E3 ubiquitin-protein ligase complex involved in interferon response and anterograde Golgi to endosome transport. The BCR(KLHL20) E3 ubiquitin ligase complex mediates the ubiquitination of DAPK1, leading to its degradation by the proteasome, thereby acting as a negative regulator of apoptosis . The BCR(KLHL20) E3 ubiquitin ligase complex also specifically mediates 'Lys-33'-linked ubiquitination . Involved in anterograde Golgi to endosome transport by mediating 'Lys-33'-linked ubiquitination of CORO7, promoting interaction between CORO7 and EPS15, thereby facilitating actin polymerization and post-Golgi trafficking . Also acts as a regulator of endothelial migration during angiogenesis by controlling the activation of Rho GTPases. The BCR(KLHL20) E3 ubiquitin ligase complex acts as a regulator of neurite outgrowth by mediating ubiquitination and degradation of PDZ-RhoGEF/ARHGEF11 . In case of tumor, the BCR(KLHL20) E3 ubiquitin ligase complex is involved in tumor hypoxia: following hypoxia, the BCR(KLHL20)complex mediates ubiquitination and degradation of PML, potentiating HIF-1 signaling and cancer progression . . |
Accessions | ENST00000209884.5 [Q9Y2M5-1] Q9Y2M5 Q9BS75 |